Erratum: CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells (Leukemia (2009) vol. 23 (1329-1336) 10.1038/leukemia.2009.77)

A. Takeshita, N. Yamakage, K. Shinjo, T. Ono, I. Hirano, S. Nakamura, K. Shigeno, T. Tobita, M. Maekawa, H. Kiyoi, T. Naoe, K. Ohnishi, Y. Sugimoto, R. Ohno

Research output: Contribution to journalComment/debatepeer-review

1 Citation (Scopus)

Fingerprint Dive into the research topics of 'Erratum: CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells (Leukemia (2009) vol. 23 (1329-1336) 10.1038/leukemia.2009.77)'. Together they form a unique fingerprint.